Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TransCon Treprostinil · ACP-009

Small molecule · developed by Ascendis Pharma

Phase 1 Most advanced trial (none active)
ASND Developer
1 Registered trials

What is TransCon Treprostinil?

TransCon Treprostinil (ACP-009) is a treprostinil product.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACP-009
Drug type
Small molecule
Developer
Ascendis Pharma A/S (ASND)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03803163 Phase 1 Healthy Volunteers Terminated ASND

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Ascendis Pharma

Lonapegsomatropin FDA approved Navepegritide FDA approved Palopegteriparatide FDA approved TransCon CNP FDA approved ACP-001 Phase 2 Resiquimod Hydrogel-based Phase 1/2 TransCon hGH Phase 3

Follow ASND, the company behind TransCon Treprostinil

See ASND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASND catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.